Literature DB >> 15448807

Bilirubin dosage in cord blood: could it predict neonatal hyperbilirubinemia?

Adélia Jeha Nasser Bernaldo1, Conceição Aparecida de Mattos Segre.   

Abstract

CONTEXT: With early discharge, many newborns have to be readmitted to hospital for hyperbilirubinemia to be treated, and this has been held responsible for the reappearance of kernicterus.
OBJECTIVE: To evaluate whether bilirubin levels in cord blood could predict neonatal hyperbilirubinemia that would require treatment, in full-term newborns up to their third day of life. TYPE OF STUDY: Prospective study.
SETTING: Neonatal Unit of Hospital Israelita Albert Einstein, São Paulo, Brazil. PARTICIPANTS: 380 full-term newborns considered normal: with or without ABO/Rh blood group incompatibility and without other complications. PROCEDURES: Blood was taken from the umbilical cord for analysis of conjugated, unconjugated and total bilirubin serum levels. The newborns were followed up until discharge, and unconjugated bilirubin that required phototherapy was compared to the cord bilirubin assay. Discriminant analysis was used to classify newborns: with or without risk of needing phototherapy by the third day of life. MAIN MEASUREMENTS: Bilirubin assay in cord blood; mother's and newborn's blood groups; phototherapy indication.
RESULTS: The mean value for unconjugated bilirubin in cord blood was significantly higher in newborns whose unconjugated bilirubin required phototherapy. The presence of ABO blood group incompatibility was a significant variable in relation to unconjugated bilirubin that required phototherapy. The most useful cutoff point for unconjugated bilirubin in cord blood was 2.0 mg/100 ml. DISCUSSION: Cord blood could be collected, stored and used for further analysis of unconjugated bilirubin levels as a means for considering whether or not to discharge a moderately jaundiced child from hospital, in association with other resources.
CONCLUSIONS: Blood incompatibility between mother and child was a predictor for the appearance of hyperbilirubinemia that required treatment. Considering a cutoff point of 2.0 mg/100 ml, it could be concluded that 53% of the newborns who had greater unconjugated bilirubin levels in cord blood would reach levels requiring phototherapy by the third day of life.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448807     DOI: 10.1590/s1516-31802004000300005

Source DB:  PubMed          Journal:  Sao Paulo Med J        ISSN: 1516-3180            Impact factor:   1.044


  6 in total

1.  Predictive value of cord blood bilirubin for hyperbilirubinemia in neonates at risk for maternal-fetal blood group incompatibility and hemolytic disease of the newborn.

Authors:  K Calkins; D Roy; L Molchan; L Bradley; T Grogan; D Elashoff; V Walker
Journal:  J Neonatal Perinatal Med       Date:  2015

2.  Post-test probability for neonatal hyperbilirubinemia based on umbilical cord blood bilirubin, direct antiglobulin test, and ABO compatibility results.

Authors:  Bart Peeters; Inge Geerts; Mia Van Mullem; Isabel Micalessi; Veroniek Saegeman; Jan Moerman
Journal:  Eur J Pediatr       Date:  2016-01-19       Impact factor: 3.183

3.  Umbilical cord blood bilirubins, gestational age, and maternal race predict neonatal hyperbilirubinemia.

Authors:  Adrian Castillo; Tristan R Grogan; Grace H Wegrzyn; Karrie V Ly; Valencia P Walker; Kara L Calkins
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

4.  Umbilical cord bilirubin as a predictor of neonatal jaundice: a retrospective cohort study.

Authors:  Kelsey D J Jones; S E Grossman; Dharshini Kumaranayakam; Arati Rao; Greg Fegan; Narendra Aladangady
Journal:  BMC Pediatr       Date:  2017-09-20       Impact factor: 2.125

5.  Ratio of cord blood bilirubin and albumin as predictors of neonatal hyperbilirubinaemia.

Authors:  Indra Kumar Sharma; Dinesh Kumar; Astitva Singh; Tariq Mahmood
Journal:  Clin Exp Hepatol       Date:  2020-12-30

6.  Applying data mining techniques to improve diagnosis in neonatal jaundice.

Authors:  Duarte Ferreira; Abílio Oliveira; Alberto Freitas
Journal:  BMC Med Inform Decis Mak       Date:  2012-12-07       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.